- Home
- TERN
as 01-17-2025 4:00pm EST
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 382.2M | IPO Year: | 2021 |
| Target Price: | $18.30 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $11.40 | Next Earning Date: | 03-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Terns Pharmaceuticals Inc. (TERN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Quigley Jill M. | TERN | Director | Jan 2 '25 | Sell | $5.72 | 6,240 | $35,702.16 | 8,760 | |
| Vignola Mark J. | TERN | Chief Financial Officer | Jan 2 '25 | Sell | $5.76 | 17,188 | $99,023.52 | 83,811 | |
| Kuriakose Emil | TERN | Chief Medical Officer | Jan 2 '25 | Sell | $5.71 | 4,481 | $25,607.12 | 54,269 | |
| Burroughs Amy L. | TERN | Chief Executive Officer | Dec 5 '24 | Buy | $7.15 | 15,450 | $110,467.50 | 19,099 |
Latest Terns Pharmaceuticals Inc. News
TERN Breaking Stock News: Dive into TERN Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
17 days ago
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Insider Monkey
a month ago
Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Simply Wall St.
a month ago
Terns Pharmaceuticals CEO & Director Acquires 423% More Stock
MT Newswires
a month ago
Oppenheimer Adjusts Price Target on Terns Pharmaceuticals to $20 From $17, Keeps Outperform Rating
GlobeNewswire
2 months ago
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
GlobeNewswire
2 months ago
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
2 months ago
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Compare TERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TERN Terns Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.